Fig. 2From: Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1Ovarian cancer cells sensitivity to different PARP inhibitors. The half maximal inhibitory concentration (IC50) of different OC cells after treatment with (a) olaparib, (b) niraparib and (c) rucaparib, assessed by clonogenic assays. Data represents the mean ± SEM of triplicates of three independent experimentsBack to article page